Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 800
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell